Literature DB >> 6107328

Progressive supranuclear palsy: clinico-pathological and biochemical studies.

K Jellinger, P Riederer, M Tomonaga.   

Abstract

Ten autopsy cases of Progressive Supranuclear Palsy (PSP) are reported. Age at onset ranged from 16 to 67 years and the duration of illness 3 to 24 years. The clinical features were aggressive mental retardation in 4 cases with early onset, paroxysmal dysequilibrium, ophthalmoplegia, rigidity and akinesia, pseudobulbar palsy and variable degrees of dementia. Neuropathology showed widespread neurofibrillary degeneration associated with system-bound neuronal loss and gliosis in subcortical areas, particularly affecting the subthalamic nucleus, substantia nigra, brainstem tegmentum and dentate nuclei, with no or little involvement of the cerebral cortex. The distribution of the lesions and the ultrastructure of the neurofibrillary tangles made of 15 nm straight filaments (seen in one case) in PSP are different from postencephalitic parkinsonism, Guam Parkinson-dementia complex and brainstem affection in (pre)senile dementia. Post-mortem biochemical analysis of two brains disclosed severe reduction of tyrosine hydroxylase, the key synthetic enzyme of the catecholamine pathway, not only in the nigrostriatal system as seen in Parkinson's disease, but in most areas of the brain-stem and limbic system. The implication and possible pathogenic and therapeutic significance of these biochemical findings are discussed. The etiology of PSP and its nosological position within the degenerative extrapyramidal disorders remain unknown.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6107328     DOI: 10.1007/978-3-7091-8582-7_12

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  28 in total

1.  A comparative immunohistochemical study on striatal Met-enkephalin expression in Alzheimer's disease and in progressive supranuclear palsy.

Authors:  S Matsumoto; S Goto; A Hirano
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

Review 2.  Corticonigral degeneration with neuronal achromasia and basal neurofibrillary tangles.

Authors:  W Paulus; M Selim
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

3.  Occurrence of 15-nm-wide straight tubules in neocortical neurons in progressive supranuclear palsy.

Authors:  H Takahashi; K Oyanagi; S Takeda; K Hinokuma; F Ikuta
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

4.  Neurofibrillary tangles in Alzheimer's disease and progressive supranuclear palsy: antigenic similarities and differences. Microtubule-associated protein tau antigenicity is prominent in all types of tangles.

Authors:  C Bancher; H Lassmann; H Budka; I Grundke-Iqbal; K Iqbal; G Wiche; F Seitelberger; H M Wisniewski
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

5.  Unusual case of corticobasal degeneration with tau/Gallyas-positive neuronal and glial tangles.

Authors:  D S Horoupian; P L Chu
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

6.  Progressive supranuclear palsy: neuropathologically based diagnostic clinical criteria.

Authors:  S J Collins; J E Ahlskog; J E Parisi; D M Maraganore
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-02       Impact factor: 10.154

7.  Further observations on Tau-positive glia in the brains with progressive supranuclear palsy.

Authors:  T Yamada; D B Calne; H Akiyama; E G McGeer; P L McGeer
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

8.  The topographic distribution of brain atrophy in Huntington's disease and progressive supranuclear palsy.

Authors:  D M Mann; R Oliver; J S Snowden
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

9.  Ferritin is associated with the aberrant tau filaments present in progressive supranuclear palsy.

Authors:  M Pérez; J M Valpuesta; E M de Garcini; C Quintana; M Arrasate; J L López Carrascosa; A Rábano; J García de Yébenes; J Avila
Journal:  Am J Pathol       Date:  1998-06       Impact factor: 4.307

10.  The pedunculopontine nucleus in Parkinson's disease, progressive supranuclear palsy and Alzheimer's disease.

Authors:  K Jellinger
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-04       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.